Arcellx Inc (ACLX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Gil Blum from Needham maintained a Buy rating on the stock and has a $81.00 price target.
Unfortunately, I cannot provide a response based on the content of the attached report as no actual report content was provided in your message. To assist you with a hypothetical analysis, I would need specific details or insights from the report that justify Gil Blum’s Buy rating for Arcellx Inc. If you can provide those details, I would be glad to help craft a response based on the information you share.
In another report released on April 4, Scotiabank also maintained a Buy rating on the stock with a $82.00 price target.
Based on the recent corporate insider activity of 31 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ACLX in relation to earlier this year.
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Arcellx Inc (ACLX) Company Description:
Arcellx Inc is a clinical-stage biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases.
